Upgrade to SI Premium - Free Trial

Piper Jaffray Cuts Price Target on Trovagene (TROV) Following 1Q Miss

May 11, 2016 8:06 AM
Piper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $5.00 (from $8.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles